Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 42

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 42
---
 Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference
as described under the heading “Incorporation of Certain Information by Reference” in this prospectus supplement and the information in any free writing prospectus that we may authorize for use in connection with
this offering. These documents contain important information that you should consider when making your investment decision.

This document
is in two parts. The first part is this prospectus supplement, which describes the specific terms of the common stock we are offering and also adds to, and updates information contained in, the accompanying prospectus and the documents incorporated
by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated by reference into the accompanying prospectus, provides more general information, some
of which may not apply to this offering. Generally, when we refer to this prospectus supplement, we are referring to the combined document consisting of this prospectus supplement and the accompanying prospectus. To the extent there is a conflict
between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference into the accompanying prospectus that was filed with the
Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a
statement in another document having a later date, for example, a document incorporated by reference into this prospectus supplement or accompanying prospectus, the statement in the document having the later date modifies or supersedes the earlier
statement.

You should rely only on the information contained in, or incorporated by reference into this prospectus supplement, the
accompanying prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Leerink Partners and Cantor have not, authorized any other person to provide you with different information.
If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only